UNLABELLED: Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. MATERIAL AND METHODS: We present the patient characteristics and treatment results of 31 consecutive, chemonaïve patients with PDECs treated with carboplatin, etoposide, and vincristine. RESULTS: The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. CONCLUSION: Treatment results with carboplatin, etoposide, and vincristine in chemonaïve patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.
UNLABELLED: Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. MATERIAL AND METHODS: We present the patient characteristics and treatment results of 31 consecutive, chemonaïve patients with PDECs treated with carboplatin, etoposide, and vincristine. RESULTS: The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. CONCLUSION: Treatment results with carboplatin, etoposide, and vincristine in chemonaïve patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.
Authors: Georg Maschmeyer; Lars-Olof Mügge; Dietrich Kämpfe; Ute Kreibich; Stephan Wilhelm; Michael Aßmann; Maik Schwarz; Christoph Kahl; Susanne Köhler; Norbert Grobe; Dietger Niederwieser Journal: J Cancer Res Clin Oncol Date: 2015-03-15 Impact factor: 4.553
Authors: Ingrid H Olsen; Jens B Sørensen; Birgitte Federspiel; Andreas Kjaer; Carsten P Hansen; Ulrich Knigge; Seppo W Langer Journal: ScientificWorldJournal Date: 2012-08-22
Authors: Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge Journal: Diagnostics (Basel) Date: 2015-04-08
Authors: Ingrid Holst Olsen; Ulrich Knigge; Birgitte Federspiel; Carsten Palnæs Hansen; Anna Skov; Andreas Kjær; Seppo W Langer Journal: J Cancer Date: 2014-08-01 Impact factor: 4.207